Opexa Therapeutics
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. Opexa's mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
About Opexa Therapeutics
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. Opexa's mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
Frequently Asked Questions
What does Opexa Therapeutics do?
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. Opexa's mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
How can I contact Opexa Therapeutics?
Visit their website at opexatherapeutics.com for more information.
Where is Opexa Therapeutics located?
The Woodlands, United States
What industry is Opexa Therapeutics in?
biotechnology
How many employees does Opexa Therapeutics have?
10-50
When was Opexa Therapeutics founded?
1986
Looking for More Company Information?
Discover more innovative companies in our comprehensive directory.
Browse All Companies